Extavia (IFN-β-1b) / Novartis  >>  Phase 4
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Extavia (IFN-β-1b) / Novartis
EPOC, NCT01216072: A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

Checkmark CMSC-ACTRIMS 2013: Multiple sclerosis (EPOC)
Jun 2013 - Jun 2013: CMSC-ACTRIMS 2013: Multiple sclerosis (EPOC)
Checkmark EPOC
May 2013 - May 2013: EPOC
Checkmark ENS 2013: Multiple sclerosis (EPOC)
More
Completed
4
1053
US, Canada
Fingolimod, GILENYA™, Standard MS DMTs, Avonex®,, Copaxone®,, Rebif®,, Betaseron®,, Extavia®
Novartis Pharmaceuticals
Relapsing Forms of Multiple Sclerosis
08/12
08/12
EPOC, NCT01317004 / 2010-024017-31: Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change

Completed
4
61
Europe
Fingolimod, GILENYA™, Standard MS DMT, Avonex®,, Copaxone®,, Rebif®,, Betaferon®,, Extavia®
Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
06/14
06/14
2011-001956-12: Biological Efficacy of Interferon ß Therapy in Patients with Multiple Sclerosis

Completed
4
85
Europe
Avonex®, Betaferon®, Rebif 22®, Rebif 44®, Extavia®, EU/1/97/033/002, EU/1/95/003/005-010, EU/1/98/063/001-003, EU/1/98/063/004-006, EU/1/08/454/001-002, EU/1/08/454/005-007, Injection, Avonex®, Betaferon®, Rebif 22®, Rebif 44®, Extavia®
University Hospital Motol
To correlate bioactivity of IFNβ reflected by level of MxA expression and clinical course of MS To measure expression of MxA protein in patients treated with IFNβ depending on NAbs status NAbs positive cohorts will be correlated NAbs titer with level of MxA expression, respectively if the MxA decrease is not preceding NAbs positivity. The MxA induction test will be tested., Biological efficacy of IFNβ treatment in patiens with multiple sclerosis will be tested with the MxA protein,which will be detected in the blood.
 
 
2012-005450-30: Investigation of neutralising antibodies against interferon-beta in patients with multiple sclerosis, in order to find markers to predict the development of these antibodies and minimize the risk of ineffective therapy Erforschung der Bildung neutralisierender Antikörper gegen Interferon-beta bei Patienten mit Multipler Sklerose. Ziel ist es, Faktoren zu finden, mit denen man die Ausbildung solcher Antikörper vorhersagen und damit das Risiko einer unwirksamen Therapie vermindern kann

Ongoing
4
50
Europe
Avonex, Rebif, Betaferon, Extavia, Avonex, Rebif, Betaferon, Extavia
Medizinische Universität Innsbruck, ABIRISK
Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis Entwicklung neutralisierender Antikörper gegen Interferon-beta in der Therapie der Multiplen Sklerose
 
 
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros.

Ongoing
4
150
Europe
Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio
Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet
Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10]
 
 
PLENO, NCT03177083 / 2016-000434-21: Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy

Completed
4
80
Europe
peginterferon beta-1a, PLEGRIDY, BIIB017, interferon beta-1a, Rebif, interferon beta-1b, Betaferon, Extavia
Biogen
Relapsing Remitting Multiple Sclerosis
10/20
10/20
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
04/30
09/30

Download Options